Plain-English translation of NCT07555210 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is looking at whether anti-PD-1 immunotherapy — a type of cancer treatment that helps your immune system fight cancer — might affect your bones and increase fracture risk. Researchers will use two types of bone imaging scans to measure your bone strength at the start of treatment, after 4-6 months, and again after 12 months. The goal is to understand if this medication causes bone weakening so doctors can better monitor and protect patients in the future.
Anti-PD-1 immunotherapy has revolutionized cancer care, but recent reports suggest it may weaken bones and increase fracture risk. Currently, there are no guidelines telling doctors to watch for this side effect, so this study aims to gather evidence about whether bone monitoring should become standard practice for patients receiving this treatment.
You likely qualify if…
You likely don't qualify if…
You would come for three imaging visits over the course of your immunotherapy treatment: one at the start, one after 4-6 months, and one after 12 months. At each visit, you'll have two different types of bone density scans — a low-dose full-body X-ray scan and a specialized 3D scan of smaller bones in your forearm. Each imaging session takes about 20-25 minutes and is completely painless. You'll also have blood work done to measure bone turnover markers.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States